CA2402160A1 - Heparinase iii and uses thereof - Google Patents

Heparinase iii and uses thereof Download PDF

Info

Publication number
CA2402160A1
CA2402160A1 CA002402160A CA2402160A CA2402160A1 CA 2402160 A1 CA2402160 A1 CA 2402160A1 CA 002402160 A CA002402160 A CA 002402160A CA 2402160 A CA2402160 A CA 2402160A CA 2402160 A1 CA2402160 A1 CA 2402160A1
Authority
CA
Canada
Prior art keywords
heparinase iii
tumor
administered
hlgag
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002402160A
Other languages
French (fr)
Other versions
CA2402160C (en
Inventor
Liu Dongfang
Kevin Pojasek
Zachary Shriver
Kristine Holley
Yosuf El-Shabrawi
Ganesh Venkataraman
Ram Sasisekharan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2402160A1 publication Critical patent/CA2402160A1/en
Application granted granted Critical
Publication of CA2402160C publication Critical patent/CA2402160C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/811—Peptides or proteins is immobilized on, or in, an inorganic carrier

Abstract

The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.

Claims (60)

1. A method for preventing proliferation of a tumor, comprising:
exposing a tumor cell to an effective amount of heparinase III for preventing proliferation of the tumor cells in order to prevent growth of the tumor.
2. The method of claim 1, wherein the heparinase III is a modified heparinase III.
3. The method of claim 1, wherein the heparinase III is a native heparinase III.
4. The method of claim 1, wherein the heparinase III is injected into the tumor in vivo.
5. The method of claim 1, wherein the heparinase III is administered systemically to a subject having a tumor.
6. The method of claim 1, wherein the heparinase III is administered orally to a subject having a tumor.
7. The method of claim 1, wherein the tumor cell is administered the heparinase III in vitro.
8. The method of claim 1, wherein the heparinase III is administered in conjunction with an anti-cancer drug.
9. The method of claim 1, wherein the heparinase III is administered to a subject having a non-metastatic tumor in order to prevent the tumor from becoming metastatic.
10. The method of claim 1, wherein the tumor is selected from the group consisting of a prostate tumor and melanoma.
11. The method of claim 1, wherein the heparinase III is administered to a subject without any additional anti-cancer drugs.
12. A method for preventing tumor cell metastasis, comprising:
exposing a tumor cell to an effective amount of heparinase III for preventing invasion of the tumor cell across a barrier.
13. The method of claim 12, wherein the heparinase III is a modified heparinase III.
14. The method of claim 12, wherein the heparinase III is a native heparinase III.
15. The method of claim 12, wherein the heparinase III is administered in vivo in conjunction with an anti-cancer drug.
16. The method of claim 12, wherein the barrier is an in vivo cell barrier.
17. The method of claim 12, wherein the barrier is an in vitro barrier of an extracellular matrix coated membrane.
18. A method for preparing therapeutic agents for the treatment for a tumor, comprising:
isolating at least a portion of a tumor, treating the portion of the tumor with heparinase III to produce HLGAG
fragments, and isolating the HLGAG fragments, wherein the HLGAG fragment is the therapeutic agent.
19. The method of claim 18, further comprising determining the sequence of the HLGAG fragments.
20. A method for treating a subject having a tumor, comprising, administering to the subject a therapeutic HLGAG fragment to treat the tumor.
21. The method of 20, wherein the therapeutic HLGAG fragment administered to the subject is a synthetic HLGAG fragment generated based on the sequence of the HLGAG fragment identified when the tumor is contacted with heparinase III.
22. The method of 20, wherein the therapeutic HLGAG fragment administered to the subject is an isolated HLGAG fragment produced when the tumor is contacted with heparinase III.
23. A composition, comprising:
heparinase III or a therapeutic HLGAG fragment in an effective amount for preventing metastasis of a tumor cell and a targeting molecule for targeting the heparinase III to the tumor, in a pharmaceutically acceptable carrier.
24. The composition of claim 23, wherein the heparinase III is a modified heparinase III.
25. The composition of claim 23, wherein the heparinase III is a native heparinase III.
26. The composition of claim 23, wherein the targeting molecule is a compound which binds specifically to an antigen on the surface of a tumor cell.
27. A composition, comprising:
heparinase III or a therapeutic HLGAG fragment in an effective amount for preventing metastasis of a tumor cell and an anti-cancer compound in a pharmaceutically acceptable carrier.
28. A substantially pure heparinase III, comprising:

a polypeptide having the amino acid sequence of the mature peptide of SEQ ID
NO:
2 or having conservative substitutions thereof within residues non-essential to enzymatic function, wherein at least one histidine residue selected from the group consisting of His 36, His105, His110, His139, His152, His225, His234, His241, His424, His469, and His539 has been substituted with a residue selected from the group consisting of alanine, serine, tyrosine, threonine, and lysine.
29. The substantially pure heparinase III of claim 28, wherein the polypeptide has at least one substitution within a histidine residue selected from the group consisting of His110 and His241.
30. The substantially pure heparinase III of claim 28, wherein the polypeptide has a substitution at His110.
31. The substantially pure heparinase III of claim 29, wherein the polypeptide has a substitution at His241.
32. A substantially pure heparinase III comprising:
a modified heparinase III having a modified product profile, wherein the modified product profile of the modified heparinase III is at least 10% different than a native product profile of a native heparinase III.
33. A substantially pure heparinase III comprising:
a modified heparinase III that can cleave a heparan sulfate substrate having a modified heparinase III kcat value, wherein the modified heparinase III kcat value is at least 10% different than a native heparinase III kcat value.
34. A pharmaceutical preparation comprising a sterile formulation of the substantially pure heparinase III of any one of claims 28-33 and a pharmaceutically acceptable carrier.
35. An immobilized substantially pure modified heparinase III comprising:

a modified heparinase III as in any one of claims 28-33, and a solid support, wherein the modified heparinase III is immobilized on the solid support.
36. A method of specifically cleaving a heparin-like glycosaminoglycan, comprising:
contacting a heparin-like glycosaminoglycan with the modified heparinase III
of any one of claims 28, 32, or 33.
37. The method of claim 36, wherein the method is a method of removing active HLGAG fragments from a HLGAG fragment containing fluid.
38. The method of claim 36, wherein the heparinase III is immobilized on a solid support.
39. The method of claim 36, wherein the method is a method for inhibiting angiogenesis and wherein an effective amount for inhibiting angiogenesis of the heparinase III is administered to a subject in need of treatment thereof.
40. The method of claim 36, wherein the heparinase III is administered to a tumor.
41. The method of claim 36, wherein the heparinase III is administered in a biodegradable, biocompatible polymeric delivery device.
42. The method of claim 36, wherein the heparinase III is administered in a pharmaceutically acceptable vehicle for injection.
43. The method of claim 42, wherein the heparinase III is administered in an effective amount for diminishing the number of blood vessels growing into a tumor.
44. The method of claim 36, wherein the heparinase III is administered in a pharmaceutically acceptable vehicle for topical application to the eye.
45. The method of claim 44, wherein the heparinase III is administered in an effective amount for diminishing the symptoms of an eye disease characterized by abnormal neovascularization.
46. The method of claim 36, wherein the heparinase III is administered in a pharmaceutical vehicle suitable for topical application.
47. The method of claim 36, wherein the heparinase III is administered in an effective amount for diminishing the symptoms of psoriasis.
48. The method of claim 36, wherein the method is a method for inhibiting cellular proliferation.
49. The method of claim 36, wherein the method is a method for sequencing HLGAG fragments.
50. A method comprising treating or preventing a subject having a cancer or at risk of developing a cancer by administering to the subject a therapeutic HLGAG
fragment.
51. The method of claim 50, wherein the therapeutic HLGAG fragment is a composition of HLGAG fragments wherein at least 50% of the HLGAG fragments are di- or tri- sulfated disaccharides.
52. The method of claim 50, wherein the therapeutic HLGAG fragment is a composition of HLGAG fragments wherein at least 75% of the HLGAG fragments are di- or tri- sulfated disaccharides.
53. The method of claim 50, wherein the therapeutic HLGAG fragment is a composition of HLGAG fragments wherein at least 90% of the HLGAG fragments are di- or tri- sulfated disaccharides.
54. The method of claim 50, wherein the therapeutic HLGAG fragment is free of mono- or un- sulfated disaccharides.
55. A method for preparing LMWH, comprising:
contacting an HLGAG sample with a modified heparinase III molecule to produce LMWH.
56. A composition, comprising, the LMWH produced by the method of claim 55.
57. A method for treating or preventing a disorder associated with coagulation, comprising:
administering to a subject an effective amount of the composition of claim 56 to treat or prevent a disorder associated with coagulation.
58. A method for treating or preventing a tumor, comprising:
administering to a subject an effective amount of the composition of claim 56 to treat or prevent a tumor in the subject.
59. A method for treating or preventing psoriasis, comprising:
administering to a subject an effective amount of the composition of claim 56 to treat or prevent psoriasis in the subject.
60. A method for treating or preventing neovascularization, comprising:
administering to a subject an effective amount of the composition of claim 56 to treat or prevent neovascularization in the subject.
CA2402160A 2000-03-08 2001-03-08 Heparinase iii and uses thereof Expired - Lifetime CA2402160C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18784600P 2000-03-08 2000-03-08
US60/187,846 2000-03-08
PCT/US2001/007464 WO2001066772A2 (en) 2000-03-08 2001-03-08 Heparinase iii and uses thereof

Publications (2)

Publication Number Publication Date
CA2402160A1 true CA2402160A1 (en) 2001-09-13
CA2402160C CA2402160C (en) 2012-02-14

Family

ID=22690719

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2402160A Expired - Lifetime CA2402160C (en) 2000-03-08 2001-03-08 Heparinase iii and uses thereof

Country Status (7)

Country Link
US (8) US6869789B2 (en)
EP (1) EP1266013B1 (en)
JP (1) JP2003525946A (en)
AU (2) AU2001243512C1 (en)
CA (1) CA2402160C (en)
ES (1) ES2527853T3 (en)
WO (1) WO2001066772A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1109919A2 (en) * 1998-08-27 2001-06-27 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
WO2000065521A2 (en) * 1999-04-23 2000-11-02 Massachusetts Institute Of Technology System and method for polymer notation
JP2003525946A (en) * 2000-03-08 2003-09-02 マサチューセッツ インスティテュート オブ テクノロジー Heparinase III and uses thereof
EP1319183B1 (en) 2000-09-12 2009-03-25 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
AU2440802A (en) 2000-10-18 2002-04-29 Massachusetts Inst Technology Methods and products related to pulmonary delivery of polysaccharides
WO2003078960A2 (en) 2002-03-11 2003-09-25 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
AU2003303301B2 (en) 2002-05-03 2008-08-07 Massachusetts Institute Of Technology Delta4,5 glycuronidase and uses thereof
US7508206B2 (en) * 2002-05-20 2009-03-24 Massachusetts Institute Of Technology Method for sequence determination using NMR
US6962699B2 (en) 2002-06-03 2005-11-08 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase B
JP4606712B2 (en) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー 2-O sulfatase compositions and related methods
US9766216B2 (en) * 2003-04-14 2017-09-19 Wako Pure Chemical Industries, Ltd. Reduction of migration shift assay interference
WO2005087920A2 (en) * 2004-03-10 2005-09-22 Massachusetts Institute Of Technology Recombinant chondroitinase abc i and uses thereof
WO2005110438A2 (en) * 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the intracellular delivery of polysaccharides
US20060127950A1 (en) * 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2005111627A2 (en) * 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2006088491A2 (en) 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
US20060154894A1 (en) * 2004-09-15 2006-07-13 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
US7691612B2 (en) * 2005-11-03 2010-04-06 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
US7767420B2 (en) 2005-11-03 2010-08-03 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
US7691613B2 (en) * 2006-11-03 2010-04-06 Momenta Pharmaceuticals, Inc. Glycosaminoglycan lyase IV and uses thereof
US8633160B2 (en) * 2005-12-30 2014-01-21 Nono Inc. Small molecule inhibitors of PDZ interactions
EP2008096A2 (en) * 2006-04-03 2008-12-31 Massachusetts Institute of Technology Glycomic patterns for the detection of disease
EP2404939A3 (en) * 2006-05-25 2012-03-21 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
US7842492B2 (en) 2007-01-05 2010-11-30 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum
US9139876B1 (en) * 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
EP2165715B1 (en) * 2007-05-29 2013-12-18 Sapporo Medical University Therapeutic agent for cancer, and method for treatment of cancer
US20110076729A1 (en) * 2008-02-20 2011-03-31 Momenta Pharmaceuticals, Inc. Methods of making low molecular weight heparin compositions
CN102791742B (en) * 2010-01-19 2014-12-24 动量制药公司 Evaluating heparin preparations
WO2012115952A1 (en) 2011-02-21 2012-08-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US20190144867A1 (en) * 2015-09-17 2019-05-16 Research Foundation Of The City University Of New York Method for mitigating metastasis
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN114703168B (en) * 2022-03-02 2023-08-18 刘颖 Heparinase III

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3766167A (en) * 1971-03-26 1973-10-16 Research Corp Orally active anticoagulant
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4281108A (en) 1980-01-28 1981-07-28 Hepar Industries, Inc. Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties, and product so obtained
JPS6040632B2 (en) * 1980-03-12 1985-09-11 松下電器産業株式会社 digital filter
US4443545A (en) 1980-08-25 1984-04-17 Massachusetts Institute Of Technology Process for producing heparinase
US4341869A (en) 1980-08-25 1982-07-27 Massachusetts Institute Of Technology Process for producing heparinase
US4373023A (en) 1980-10-14 1983-02-08 Massachusetts Institute Of Technology Process for neutralizing heparin
US4396762A (en) 1981-08-24 1983-08-02 Massachusetts Institute Of Technology Heparinase derived anticoagulants
US4551296A (en) * 1982-03-19 1985-11-05 Allied Corporation Producing high tenacity, high modulus crystalline article such as fiber or film
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1226816A (en) 1982-12-20 1987-09-15 Moses J. Folkman Inhibition of angiogenesis
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
FR2553287B1 (en) 1983-10-18 1986-09-12 Choay Sa COMPOSITIONS BASED ON MUCOPOLYSACCHARIDES OR OLIGOSACCHARIDES, ESPECIALLY BASED ON HEPARIN FRACTIONS OR FRAGMENTS, SUITABLE FOR THE TREATMENT OF CELL PROLIFERATION DISORDERS
US4757056A (en) 1984-03-05 1988-07-12 Hepar Industries, Inc. Method for tumor regression in rats, mice and hamsters using hexuronyl hexosaminoglycan-containing compositions
US4679555A (en) * 1984-08-07 1987-07-14 Key Pharmaceuticals, Inc. Method and apparatus for intrapulmonary delivery of heparin
US5262403A (en) 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
DK196986D0 (en) * 1986-04-30 1986-04-30 Novo Industri As PREPARATION OF POLYSACCHARIDES
US5106734A (en) 1986-04-30 1992-04-21 Novo Nordisk A/S Process of using light absorption to control enzymatic depolymerization of heparin to produce low molecular weight heparin
US4942156A (en) 1986-08-20 1990-07-17 Hepar Industries, Inc. Low molecular weight heparin derivatives having improved anti-Xa specificity
US4745105A (en) 1986-08-20 1988-05-17 Griffin Charles C Low molecular weight heparin derivatives with improved permeability
US4830013A (en) * 1987-01-30 1989-05-16 Minnesota Mining And Manufacturing Co. Intravascular blood parameter measurement system
FR2614026B1 (en) 1987-04-16 1992-04-17 Sanofi Sa LOW MOLECULAR WEIGHT HEPARINS WITH REGULAR STRUCTURE, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS
SE8702254D0 (en) 1987-05-29 1987-05-29 Kabivitrum Ab NOVEL HEPARIN DERIVATIVES
US5217705A (en) 1987-09-25 1993-06-08 Neorx Corporation Method of diagnosing blood clots using fibrin-binding proteins
US5169772A (en) 1988-06-06 1992-12-08 Massachusetts Institute Of Technology Large scale method for purification of high purity heparinase from flavobacterium heparinum
IT1234508B (en) 1988-06-10 1992-05-19 Alfa Wassermann Spa HEPARIN DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION
US5204323B1 (en) 1988-10-06 1995-07-18 Ciba Geigy Corp Hirudin antidotal compositions and methods
GB8826448D0 (en) 1988-11-11 1988-12-14 Thrombosis Res Inst Improvements in/relating to organic compounds
JPH0693836B2 (en) * 1988-11-25 1994-11-24 新技術事業団 Heparinase-producing microorganism belonging to the genus Bacillus, novel heparinase, and method for producing the same
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
PT93847A (en) 1989-04-24 1990-11-20 Harvard College PROCESS FOR THE PREPARATION OF OLIGOSACARIDES OF LOW MOLECULAR WEIGHT DERIVED FROM HEPARIN OR DESPOLYMENED HEPARAN SULFATE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
CA1340966C (en) * 1989-05-19 2000-04-18 Thomas R. Covey Method of protein analysis
IT1237518B (en) 1989-11-24 1993-06-08 Renato Conti SUPER-SULFATED HEPARINS
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5152784A (en) 1989-12-14 1992-10-06 Regents Of The University Of Minnesota Prosthetic devices coated with a polypeptide with type IV collagen activity
JPH04167172A (en) 1990-10-31 1992-06-15 Nec Corp Vector processor
IT1245761B (en) 1991-01-30 1994-10-14 Alfa Wassermann Spa PHARMACEUTICAL FORMULATIONS CONTAINING GLYCOSAMINOGLICANS ABSORBABLE ORALLY.
JP3110064B2 (en) 1991-03-06 2000-11-20 生化学工業株式会社 Novel heparitinase, method for producing the same and bacteria producing the same
US5262325A (en) 1991-04-04 1993-11-16 Ibex Technologies, Inc. Method for the enzymatic neutralization of heparin
HUT67136A (en) 1991-05-02 1995-02-28 Yeda Res & Dev Compositions for the prevention and/or treatment of pathological processes
WO1993005167A1 (en) * 1991-09-06 1993-03-18 Children's Medical Center Corporation Cell-type specific heparan sulfate proteoglycans and their uses
US5714376A (en) 1991-10-23 1998-02-03 Massachusetts Institute Of Technology Heparinase gene from flavobacterium heparinum
AU3144993A (en) 1991-11-21 1993-06-15 Glyko, Inc. Fluorophore-assisted therapeutic drug monitoring
GB9202019D0 (en) 1992-01-30 1992-03-18 Imperial College Methods and apparatus for assay of sulphated polysaccharides
IT1254216B (en) 1992-02-25 1995-09-14 Opocrin Spa POLYSACCHARIDIC DERIVATIVES OF HEPARIN, EPARAN SULPHATE, THEIR FRACTIONS AND FRAGMENTS, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5453171A (en) * 1992-03-10 1995-09-26 The Board Of Regents Of The University Of Michigan Heparin-selective polymeric membrane electrode
US5856928A (en) * 1992-03-13 1999-01-05 Yan; Johnson F. Gene and protein representation, characterization and interpretation process
GB9206291D0 (en) * 1992-03-23 1992-05-06 Cancer Res Campaign Tech Oligosaccharides having growth factor binding affinity
AU3938093A (en) 1992-04-02 1993-11-08 Baker Norton Pharmaceuticals, Inc. Method and composition for treating antigen-induced and exercise-induced asthma
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5569801A (en) * 1992-08-27 1996-10-29 Fina Research, S.A. Polymer conversion process
US5389539A (en) 1992-11-30 1995-02-14 Massachusetts Institute Of Technology Purification of heparinase I, II, and III from Flavobacterium heparinum
US5696100A (en) 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
GB9306255D0 (en) 1993-03-25 1993-05-19 Cancer Res Campaign Tech Heparan sulphate oligosaccharides having hepatocyte growth factor binding affinity
FR2704861B1 (en) 1993-05-07 1995-07-28 Sanofi Elf Purified heparin fractions, process for obtaining them and pharmaceutical compositions containing them.
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
WO1995013830A1 (en) 1993-11-17 1995-05-26 Massachusetts Institute Of Technology Method for inhibiting angiogenesis using heparinase
US6013628A (en) 1994-02-28 2000-01-11 Regents Of The University Of Minnesota Method for treating conditions of the eye using polypeptides
US5607859A (en) * 1994-03-28 1997-03-04 Massachusetts Institute Of Technology Methods and products for mass spectrometric molecular weight determination of polyionic analytes employing polyionic reagents
US5753445A (en) 1994-04-26 1998-05-19 The Mount Sinai Medical Center Of The City University Of New York Test for the detection of anti-heparin antibodies
WO1995030424A1 (en) 1994-05-06 1995-11-16 Glycomed Incorporated O-desulfated heparin derivatives, methods of making and uses thereof
US5681733A (en) 1994-06-10 1997-10-28 Ibex Technologies Nucleic acid sequences and expression systems for heparinase II and heparinase III derived from Flavobacterium heparinum
US5619421A (en) 1994-06-17 1997-04-08 Massachusetts Institute Of Technology Computer-implemented process and computer system for estimating the three-dimensional shape of a ring-shaped molecule and of a portion of a molecule containing a ring-shaped structure
US5997863A (en) * 1994-07-08 1999-12-07 Ibex Technologies R And D, Inc. Attenuation of wound healing processes
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
FR2723847A1 (en) 1994-08-29 1996-03-01 Debiopharm Sa HEPARIN - BASED ANTITHROMBOTIC AND NON - HEMORRHAGIC COMPOSITIONS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC APPLICATIONS.
US5687090A (en) * 1994-09-01 1997-11-11 Aspen Technology, Inc. Polymer component characterization method and process simulation apparatus
WO1996011671A1 (en) * 1994-10-12 1996-04-25 Focal, Inc. Targeted delivery via biodegradable polymers
US5569366A (en) * 1995-01-27 1996-10-29 Beckman Instruments, Inc. Fluorescent labelled carbohydrates and their analysis
US5618917A (en) 1995-02-15 1997-04-08 Arch Development Corporation Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells
US5763427A (en) 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
AU720963B2 (en) 1995-05-26 2000-06-15 Surmodics, Inc. Method and implantable article for promoting endothelialization
US5824299A (en) 1995-06-22 1998-10-20 President & Fellows Of Harvard College Modulation of endothelial cell proliferation with IP-10
US5690910A (en) 1995-08-18 1997-11-25 Baker Norton Pharmaceuticals, Inc. Method for treating asthma
ES2227611T3 (en) * 1995-09-29 2005-04-01 Biomarin Pharmaceutical Inc USE OF HEPARINES TO DECREASE INFLAMMATORY SPARE PARTS.
US6217863B1 (en) 1995-10-30 2001-04-17 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase I
US5752019A (en) * 1995-12-22 1998-05-12 International Business Machines Corporation System and method for confirmationally-flexible molecular identification
GB9606188D0 (en) 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
BR9709748A (en) * 1996-04-29 2000-01-11 Dura Pharma Inc Dry powder inhalation method
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
AU3892297A (en) 1996-07-26 1998-02-20 Ikonos Corporation Sensor for detecting heparin and other analytes
WO1998004133A1 (en) * 1996-07-29 1998-02-05 Cavalier Pharmaceuticals Methods of treating asthma with o-desulfated heparin
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
US5759767A (en) * 1996-10-11 1998-06-02 Joseph R. Lakowicz Two-photon and multi-photon measurement of analytes in animal and human tissues and fluids
JP3884484B2 (en) 1997-01-16 2007-02-21 マサチューセッツ インスティチュート オブ テクノロジー Preparation of particles for inhalation
US5968822A (en) 1997-09-02 1999-10-19 Pecker; Iris Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
US6190875B1 (en) * 1997-09-02 2001-02-20 Insight Strategy & Marketing Ltd. Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe
US6268146B1 (en) * 1998-03-13 2001-07-31 Promega Corporation Analytical methods and materials for nucleic acid detection
EP1109919A2 (en) 1998-08-27 2001-06-27 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
US7056504B1 (en) * 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
US6291439B1 (en) * 1998-09-02 2001-09-18 Biomarin Pharmaceuticals Methods for diagnosing atherosclerosis by measuring endogenous heparin and methods for treating atherosclerosis using heparin
US6333051B1 (en) * 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
WO2000065521A2 (en) * 1999-04-23 2000-11-02 Massachusetts Institute Of Technology System and method for polymer notation
JP2003525946A (en) * 2000-03-08 2003-09-02 マサチューセッツ インスティテュート オブ テクノロジー Heparinase III and uses thereof
EP1319183B1 (en) 2000-09-12 2009-03-25 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
AU2440802A (en) 2000-10-18 2002-04-29 Massachusetts Inst Technology Methods and products related to pulmonary delivery of polysaccharides
US20030008820A1 (en) * 2001-03-27 2003-01-09 Massachusetts Institute Of Technology Methods and products related to FGF dimerization
AU2003303301B2 (en) * 2002-05-03 2008-08-07 Massachusetts Institute Of Technology Delta4,5 glycuronidase and uses thereof
US7508206B2 (en) * 2002-05-20 2009-03-24 Massachusetts Institute Of Technology Method for sequence determination using NMR
US6962699B2 (en) * 2002-06-03 2005-11-08 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase B
JP4606712B2 (en) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー 2-O sulfatase compositions and related methods
WO2005087920A2 (en) * 2004-03-10 2005-09-22 Massachusetts Institute Of Technology Recombinant chondroitinase abc i and uses thereof
WO2005110438A2 (en) * 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the intracellular delivery of polysaccharides
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2005111627A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2006088491A2 (en) 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
US20060154894A1 (en) * 2004-09-15 2006-07-13 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
WO2006076627A2 (en) 2005-01-12 2006-07-20 Massachusetts Institute Of Technology Methods and compositions related to modulating the extracellular stem cell environment
US20090155875A1 (en) 2005-02-16 2009-06-18 Massachusetts Institute Of Technology Methods to Enhance Carbon Monoxide Dehydrogenase Activity and Uses Thereof
US20090105463A1 (en) 2005-03-29 2009-04-23 Massachusetts Institute Of Technology Compositions of and Methods of Using Oversulfated Glycosaminoglycans
WO2006105315A2 (en) 2005-03-29 2006-10-05 Massachusetts Institute Of Technology Compositions and methods for regulating inflammatory responses
EP2008096A2 (en) 2006-04-03 2008-12-31 Massachusetts Institute of Technology Glycomic patterns for the detection of disease

Also Published As

Publication number Publication date
AU4351201A (en) 2001-09-17
AU2001243512C1 (en) 2008-04-17
AU2001243512B2 (en) 2007-05-10
US7939292B2 (en) 2011-05-10
WO2001066772A2 (en) 2001-09-13
WO2001066772A3 (en) 2002-05-02
US20120027744A1 (en) 2012-02-02
US7455986B2 (en) 2008-11-25
WO2001066772A9 (en) 2005-03-10
US20090081635A1 (en) 2009-03-26
US7390633B2 (en) 2008-06-24
US6869789B2 (en) 2005-03-22
JP2003525946A (en) 2003-09-02
EP1266013B1 (en) 2014-10-15
US20060067928A1 (en) 2006-03-30
US20020122793A1 (en) 2002-09-05
US20050233402A1 (en) 2005-10-20
US20060182734A1 (en) 2006-08-17
ES2527853T3 (en) 2015-01-30
US20030099628A1 (en) 2003-05-29
EP1266013A2 (en) 2002-12-18
CA2402160C (en) 2012-02-14
US20060183713A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
CA2402160A1 (en) Heparinase iii and uses thereof
JP2003525946A5 (en)
US9956273B2 (en) Compositions and methods for promoting neuronal outgrowth
JP5756785B2 (en) Soluble hyaluronidase glycoprotein (sHASEGP), process for its preparation, use and pharmaceutical composition comprising it
HUT68905A (en) Pharmaceutical compositions for wound healing and treatment of fibrotic disorders and process for production of them
CA2901795C (en) Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
JP2003527822A5 (en)
JP2004504262A (en) Attenuated fibroblast proliferation
JP2019116487A (en) Glycoprotein having lipid mobilization characteristics, and therapeutic usage of the same
EP2155237B1 (en) Glycosylasparaginase for treatment of cancer
KR20150139982A (en) Novel neurturin conjugates for pharmaceutical use
JPH11514352A (en) Urokinase plasminogen activator fragment
WO2007049424A1 (en) Hepatic fibrosis inhibitor
US20040121958A1 (en) Methods of alleviating neuropathic pain
Dive et al. Dosing and scheduling influence the antitumor efficacy of a phosphinic peptide inhibitor of matrix metalloproteinases
EP2802342B1 (en) Peptide and uses thereof
US6566339B1 (en) Pharmaceutical composition
AU783222B2 (en) Attenuation of tumor growth, metastasis and angiogenesis by use of chondroitin sulfate degrading enzymes
TW201720840A (en) Short synthetic peptide and uses thereof
US20020068054A1 (en) Therapeutic and cosmetic uses of heparanases
US20080249027A1 (en) CHEC-7 a novel sPLA2 inhibitor and methods of use for treating neurological and inflammatory disorders
US20050164985A1 (en) Therapeutic application of enoxaparin
WO2012136768A1 (en) Use of mutants of human hyaluronidase ph-20 with increased chondroitinase activity for axonal regrowth
RU2799211C2 (en) Agent for the treatment of dermatological diseases
US20020151481A1 (en) MMP-2 propeptide for use as antiangiogenic or antitumor agent

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20210308